TY - JOUR
T1 - How to RESPOND to modern challenges for people living with HIV
T2 - A profile for a new cohort consortium
AU - AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA)
AU - The Australian HIV Observational Database (AHOD)
AU - Austrian HIV Cohort Study (AHIVCOS)
AU - CHU Saint-Pierre
AU - EuroSIDA Cohort
AU - Infectious Diseases, AIDS and Clinical Immunology Research Center (IDACIRC)
AU - Italian Cohort Naive Antiretrovirals (ICONA)
AU - Modena HIV Cohort
AU - Nice HIV Cohort
AU - PISCIS Cohort Study
AU - The RESPOND study group
AU - Wit, F.
AU - Reiss, P.
AU - Hillebregt, M.
AU - Law, M.
AU - Petoumenos, K.
AU - Rose, N.
AU - Hutchinson, J.
AU - Zangerle, R.
AU - Appoyer, H.
AU - De Wit, S.
AU - Delforge, M.
AU - Wandeler, Gilles
AU - Stephan, C.
AU - Bucht, M.
AU - Chkhartishvili, N.
AU - Chokoshvili, O.
AU - D’Arminio Monforte, A.
AU - Rodano, A.
AU - Tavelli, A.
AU - Fanti, I.
AU - Mussini, C.
AU - Borghi, V.
AU - Pradier, C.
AU - Fontas, E.
AU - Dollet, K.
AU - Caissotti, C.
AU - Casabona, J.
AU - Miro, J. M.
AU - Riera, A.
AU - Reyes-Urueña, J.
N1 - Funding Information:
Funding: The International Cohort Consortium of Infectious Disease (RESPOND) has received funding from ViiV Healthcare LLC and Gilead Sciences. Additional support has been provided by participating cohorts contributing data in-kind: Austrian HIV Cohort Study (AHIVCOS), The Australian HIV Observational Database (AHOD), CHU Saint-Pierre, University Hospital Cologne, The EuroSIDA cohort, Frankfurt HIV Cohort Study, Georgian National AIDS Health Information System (AIDS HIS), Modena HIV Cohort, San Raffaele Scientific Institute, Swiss HIV Cohort Study (SHCS), AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA), and the Royal Free HIV Cohort Study.
Publisher Copyright:
© 2020 by the author. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8
Y1 - 2020/8
N2 - Background: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases. Methods: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12. Results: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40–56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8–17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438–830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events. Conclusion: RESPOND’s large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.
AB - Background: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases. Methods: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12. Results: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40–56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8–17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438–830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events. Conclusion: RESPOND’s large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.
KW - Cohort
KW - Hepatitis
KW - HIV
KW - Observational study
KW - Pharmacovigilance
KW - Public health
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85090524083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090524083&partnerID=8YFLogxK
U2 - 10.3390/microorganisms8081164
DO - 10.3390/microorganisms8081164
M3 - Article
AN - SCOPUS:85090524083
VL - 8
SP - 1
EP - 17
JO - Microorganisms
JF - Microorganisms
SN - 2076-2607
IS - 8
M1 - 1164
ER -